BioXcel closes $57.5 million sale to Teva; liquidating plan heads to December 3 confirmation hearing
ElevenFlo ·
BioXcel, renamed BX Liquidation, Inc. on November 16 Dkt. 339, has closed its court-approved sale to Teva for $57.5 million in cash plus up to $67.5 million in FDA- and sales-linked milestones allsci.com: Teva swoops for BioXcel neuroscience assets in bankruptcy sale for up to USD 125m ahead of FDA decision (outside source). At a hearing set for December 3, 2026, the debtors will ask Judge Horan to confirm their liquidating plan, which sends the sale value to the secured lenders, over the general unsecured class's rejection Dkt. 331.
Jump to section
No rival bid emerged, so Teva's stalking-horse offer of $57.5 million in cash plus up to $67.5 million in contingent milestones became the approved sale, and it closed within a week. The plan would pass the sale value to the secured lenders and wind down the estates through a liquidation trust.
The bankruptcy court approved the sale of BioXcel's assets to Teva Pharmaceuticals International GmbH on October 21, 2026, free and clear of liens, claims and interests Dkt. 267. The sale has since closed. AllSci reported on October 27 that Teva had announced its acquisition of worldwide rights to BXCL501 and IGALMI after court approval and satisfaction of closing conditions allsci.com: Teva swoops for BioXcel neuroscience assets in bankruptcy sale for up to USD 125m ahead of FDA decision (outside source), and the debtors' November 16 designation of the appellate record lists a notice of sale closing Dkt. 334. The consideration is $57.5 million in cash at closing, less the deposit and any cure costs above a $2.5 million cap, plus contingent development and commercial milestone payments and the assumption of specified liabilities Dkt. 267. No other qualified bid arrived by the October 9 bid deadline Dkt. 258, so under the bidding procedures no auction was held and Teva stood as the successful bidder Dkt. 179. The court found Teva to be a good-faith purchaser and granted it the protection of section 363(m) Dkt. 267.
The debtors now seek confirmation of their Second Amended Combined Disclosure Statement and Chapter 11 Plan, a liquidating plan that grants no discharge Dkt. 274. On November 13 they filed the plan supplement Dkt. 330 and a proposed order that would approve the disclosure statement on a final basis and confirm the plan at a hearing on December 3, 2026 at 11:00 a.m. ET before Judge Thomas M. Horan Dkt. 331. The proposed order would confirm the plan under section 1129(b) despite rejection by Class 4 general unsecured creditors and the deemed rejection of other impaired classes. On November 16 the court authorized BioXcel to change its corporate name to BX Liquidation, Inc. and changed the case caption Dkt. 339.
Part of the Teva consideration depends on the FDA. The target action date for the supplemental new drug application for at-home use of IGALMI was November 14, 2026 Dkt. 2, and the filings do not report the FDA's decision. Approval by November 21, 2026 earns the maximum $67.5 million development milestone, which is the assumption behind the debtors' recovery estimates Dkt. 274. Approval between November 22, 2026 and February 28, 2027 would cut that payment to $55 million Dkt. 13. Separately, Shawn Richeson has appealed the sale order. The debtors' designation of additional record items for that appeal lists Richeson's emergency motion, his withdrawal notice and his motion to designate supplemental items, along with the notice of sale closing Dkt. 334.
No rival bid emerged, and Teva's stalking-horse deal was approved and closed
BioXcel retained MTS Health Partners as investment banker on November 7, 2025 Dkt. 25 and used Rodman & Renshaw as placement agent in a dual-track process seeking either new equity capital or a buyer or strategic partner. MTS contacted more than 40 potential acquirers. Twelve held meetings, and seven signed nondisclosure agreements and received data-room access, according to the declaration of MTS partner Daun Chung Dkt. 14. Teva emerged as the most viable bidder and submitted a non-binding letter of intent for a section 363 sale with Teva as stalking horse Dkt. 25. Cooley LLP and Young Conaway Stargatt & Taylor, LLP are the debtors' legal counsel finanznachrichten.de: Cooley LLP and Young Conaway Stargatt & Taylor, LLP (outside source), and Stretto is the claims and noticing agent markets.businessinsider.com: Stretto, Inc. is serving as the claims and noticing agent (outside source).
On July 1, 2026, the board formed a Strategic Process Committee with exclusive authority to negotiate any financing, sale or chapter 11 filing. Director David Mack initially chaired it, and director Susan Atkins joined after her appointment on August 12, 2026. The same day, the board formed a Claims Committee, with Atkins as its sole member, to investigate potential claims against current and former officers, directors and other third parties Dkt. 2.
The bidding procedures order, entered September 28, 2026, approved the stalking-horse agreement and Teva's bid protections Dkt. 179. These were a $1.15 million break-up fee, rising to $5 million if the FDA approval was obtained before termination, plus expense reimbursement capped at $575,000, all as superpriority administrative claims. The order set the October 9 bid deadline, an October 14 auction if needed and the October 21 sale hearing. It also barred the DIP and prepetition secured parties from credit bidding for the assets covered by Teva's bid while the agreement remained in force and Teva was not in material breach.
Under the stalking-horse APA, Teva pays $57.5 million at closing, assumes specified liabilities and may make milestone payments Dkt. 13. The four development-payment tiers depend on when the FDA approves the pending supplemental new drug application for at-home use of IGALMI. Only one development payment is payable, and closing must occur before any is due. Teva's parent, Teva Pharmaceutical Industries Ltd., guarantees the milestone payment obligations, according to Insider Monkey insidermonkey.com: Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity? (outside source).
- By Nov 21, 2026$67.5M
- Nov 22, 2026 to Feb 28, 2027$55.0M
- Mar 1 to May 31, 2027$20.0M
- Jun 1 to Nov 30, 2027$5.0M
Show the numbers
| FDA approval window | Development payment |
|---|---|
| By Nov 21, 2026 | $67.5M |
| Nov 22, 2026 to Feb 28, 2027 | $55.0M |
| Mar 1 to May 31, 2027 | $20.0M |
| Jun 1 to Nov 30, 2027 | $5.0M |
Source: stalking-horse APA, section 2.3.2, filed with the bidding procedures motion Dkt. 13
If approval is not received by February 28, 2027, the agreement also provides for commercial milestone payments Dkt. 13. One $10 million payment depends on first achieving annual net sales of at least $250 million by December 31, 2035. A further $10 million depends on first reaching $500 million in annual net sales by that date. Neither commercial payment is payable if either of the two highest development milestone events is achieved.
The chart shows the stated development amounts before deductions. APA section 2.3.2 lets specified third-party intellectual-property payments reduce an unpaid milestone, subject to contractual limits and exclusions, including a cap of half the otherwise payable milestone amount Dkt. 13.
The sale order makes cure costs payable at closing, or by the assignment date for contracts assigned later, and splits transfer taxes evenly between Teva and the sellers Dkt. 267. It bars successor-liability claims against Teva, except for permitted encumbrances and assumed liabilities, and preserves the parties' rights and objections on the ProPharma contracts. Teva closed a deal in June to acquire neuroscience biotech Emalex Biosciences for up to $900 million biospace.com: BioXcel files for bankruptcy, will sell assets to Teva for up to $125M (outside source). Its executive vice president of business development, Evan Lippman, described the BioXcel transaction as strengthening Teva's neuroscience portfolio biospace.com: BioXcel files for bankruptcy, will sell assets to Teva for up to $125M (outside source).
The plan sends sale value to the lenders and caps the unsecured reserve at $1 million
The debtors first filed their combined plan and disclosure statement on September 30, 2026 Dkt. 196. They amended it on October 19 and October 20 and filed the solicitation version on October 21, the day of the sale hearing. That version transfers the debtors' remaining assets and retained causes of action to a liquidation trust on the effective date Dkt. 274. The plan supplement names Scott Canna as liquidation trustee, with Portage Point Partners assisting Dkt. 330. The trustee's monthly pay would be $15,000 for the first three months, $10,000 for the next three and $5,000 after that. The DIP and prepetition lenders would have consultation rights while their claims remain unpaid, and certain professional-retention and settlement decisions would need their written consent.
Allowed DIP claims are paid in cash on the effective date unless their holders agree otherwise. If they are not paid in full at the sale closing, the contingent payment rights under the Teva agreement may be assigned to the DIP agent Dkt. 247. Class 3 prepetition secured claims then take the remaining distributable cash, capped at the allowed claim, and any shortfall becomes a Class 4 deficiency claim Dkt. 274. General unsecured creditors look mainly to a GUC Recovery Reserve funded with 30% of the proceeds of retained causes of action, capped at $1 million. Lender deficiency claims rank behind other Class 4 claims in that reserve. The plan supplement states that, apart from the reserve, retained-cause proceeds are not expected to reach Class 4 until the DIP and prepetition secured claims are paid in full Dkt. 330.
| Class | Status | Treatment |
|---|---|---|
| 1. Priority non-tax claims | Unimpaired | Paid in full |
| 2. Other secured claims | Unimpaired | Paid in full |
| 3. Prepetition secured claims | Impaired; entitled to vote | Pro rata share of the distributable cash left after DIP claims, plus contingent payment rights and trust assets as the plan provides, capped at the allowed claim; any shortfall becomes a Class 4 deficiency claim. Estimated recovery 84.4%. |
| 4. General unsecured claims | Impaired; voted to reject, per the proposed confirmation order Dkt. 331 | Pro rata share of the GUC Recovery Reserve and remaining trust assets after senior claims and reserves. Estimated recovery 0% to 2.9%. |
| 5. Intercompany claims | No distribution | Adjusted, reinstated or discharged without distribution |
| 6 and 7. Subordinated and section 510(b) claims | Impaired; deemed to reject | Residual trust distributions only after senior claims are paid or reserved |
| 8. Interests | Impaired; deemed to reject | Cancelled |
The first amended plan's liquidation analysis estimates Class 3 recovery at 84.4% ($45.408 million) under the plan and 84.3% ($45.348 million) in chapter 7, with no recovery for ordinary Class 4 claims in either case Dkt. 247. It assumes a sale closing on October 26, 2026, conversion to chapter 7 around December 17, 2026 in the comparison case, and FDA approval by November 21, 2026. On that basis it counts the full $67.5 million development milestone, applied first to the DIP facility and then to the prepetition secured claim, and gives no value to commercial milestones. It shows the Class 4 reserve at zero because it does not quantify proceeds from retained causes of action. The solicitation version keeps the 84.4% and 84.3% estimates and the $67.5 million assumption Dkt. 274. The second amended plan put the general unsecured recovery at 0% to 2.9% Dkt. 258.
The schedule of retained causes of action covers insurance, avoidance actions, litigation and claims to enforce the purchase agreement, and it states that the Claims Committee's investigation remains open Dkt. 330. The debtor releases are subject to that investigation, and Exhibit G of the supplement lists no current exclusions from the exculpated parties. The wind-down budget totals $2 million. The trustee would reassess the wind-down reserve by June 30, 2027, and the administrative claim reserve amount is blank in the filed draft. The debtors are not proposing a section 510(b) calculation method; the trustee would seek court approval of one if assets become available for those claims.
Effectiveness requires a final confirmation order, consummation of the sale, funded reserves, an executed trust agreement and an appointed trustee, and payment or agreed treatment of DIP claims Dkt. 247. The proposed confirmation order would set a deadline 30 days after the effective date for most postpetition administrative claims and 45 days for final fee applications Dkt. 331.
Securities litigation, contract rejections and the subsidiary cases are being cleared before confirmation
On November 16 the court approved a $9.75 million cash settlement of securities litigation brought by Tonya Hills and the Oklahoma Law Enforcement Retirement System against BioXcel, Vimal Mehta, Richard Steinhart and Robert Risinger Dkt. 333. The defendants' insurers fund the settlement into escrow. The order modifies the automatic stay so the district court can hold a final approval hearing and, once it approves the settlement, so the escrowed funds can be released. It bars collection against estate property other than the debtors' interest, if any, in the escrowed amount. District court final approval is still required.
BioSignal Therapeutics, LLC, which describes itself as a BioXcel shareholder, has offered $1 million in cash and a $5 million promissory note payable in $1 million annual installments, plus cure costs, for the 701/702 patents and related oncology assets Dkt. 324. It objected on November 12 to the debtors' five omnibus rejection motions to preserve contracts tied to those assets, then withdrew the objection with prejudice the next day Dkt. 326. The agenda for the November 18 hearing listed the rejection motions as uncontested. It also said the debtors were discussing a potential counterparty's possible acquisition of certain listed contracts and might adjourn those matters Dkt. 332.
The debtors have asked the court to close the cases of OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC, keeping the BioXcel lead case open and handling any remaining matters there Dkt. 325. They argue the affiliate cases will be fully administered upon confirmation and the effective date. Objections are due November 30, and the motion is set for the December 3 hearing.
The debtors have filed a first omnibus substantive objection to claims and asked to file under seal the KERP and retention award amounts in its supporting exhibits Dkt. 321. Latham & Watkins, the largest unsecured creditor on the petition list, filed an ordinary-course professional declaration to keep handling the securities class-action and derivative litigation at a blended hourly rate of $1,800 Dkt. 315. The firm reports $8,133,533 owed for prepetition services and expects insurers to pay certain fees. MERU, LLC, whose managing director Samir Saleem is the debtors' chief restructuring officer, requested $517,200 in fees and $10,741.17 in expenses for October Dkt. 329.
A trial-site misconduct disclosure and one slow-selling product led to the filing
BioXcel's only marketed product is IGALMI (dexmedetomidine) sublingual film, approved by the FDA in April 2022 for acute agitation associated with schizophrenia or bipolar I or II disorder. IGALMI generated $0.6 million in revenue in 2025, down from $2.3 million in 2024, and the company reported a $27.4 million net loss for the six months ended June 30, 2026 Dkt. 2. The first-day declaration attributes the filing to slow commercial adoption of IGALMI and revenue too small to cover operating expenses, debt service and clinical development.
The company's TRANQUILITY Phase 3 trial, testing BXCL501 for agitation associated with Alzheimer's dementia, produced positive topline results on June 29, 2023. The same announcement disclosed that a contract research organization's principal investigator had submitted a falsified email to the FDA during a clinical-site inspection. BioXcel's stock price fell about 64% in a single day after the disclosure Dkt. 2. The company says this impaired its ability to raise the equity needed to fund both the at-home IGALMI label expansion and a restart of the TRANQUILITY program. BioXcel's shares had fallen about 55% during 2026 before the filing kfgo.com: Biopharma firm BioXcel Therapeutics files for bankruptcy in US (outside source), on top of the 2023 decline.
In August 2023, the board approved a Clinical Reprioritization that concentrated resources on the at-home SERENITY program. It paused TRANQUILITY, BXCL502, BXCL503, BXCL504 and further development of BXCL701, which is held through OnkosXcel. BioXcel cut its workforce by approximately 15% in May 2024 and by a further 28% in September 2024 Dkt. 2. Headcount fell from about 60 employees to 25 full-time employees as of the petition date.
BioXcel and two subsidiaries, OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC, filed chapter 11 petitions in the U.S. Bankruptcy Court for the District of Delaware on August 27, 2026 Dkt. 1. The court ordered joint administration under BioXcel's case, No. 26-11360, for procedural purposes only Dkt. 52.
All $111.8 million of funded debt sits with one secured lender group
BioXcel entered its senior secured Credit Agreement and a companion instrument, the RIFA, in April 2022. Together they provided for up to $260 million in financing from funds affiliated with Oaktree Capital Management and the Qatar Investment Authority, with Oaktree Fund Administration, LLC as administrative agent Dkt. 2. The company drew $70 million under the initial Credit Agreement tranche and $30 million under the RIFA, for $100 million in total funded proceeds. The RIFA was terminated in December 2023, and its balance was converted into term loans.
The solicitation-version plan reports approximately $111,755,133.46 in principal amount of funded debt as of the petition date, consisting entirely of obligations under the Credit Agreement and excluding fees, interest, costs and expenses Dkt. 274 · p. 30. In the final DIP order, the debtors stipulated that they owed not less than that amount, including interest that was paid in kind and capitalized before the petition date Dkt. 149 · p. 8. The first-day declaration rounded the figure to approximately $112 million Dkt. 2 · p. 10. BioXcel is the borrower, and both subsidiaries guarantee the loans.
The loans bear 13.0% fixed annual interest, payable quarterly in cash. BioXcel could elect payment-in-kind interest through June 30, 2025, and those payments were capitalized into principal Dkt. 2 · p. 12. A 0.50% exit fee applies to principal repaid, and the stated maturity is April 19, 2027. The loans are secured by a first-priority lien on substantially all of the debtors' assets, including BioXcel's equity in both subsidiaries.
The debtors also estimate about $17 million of unpaid trade and other ordinary-course obligations, much of it owed to current or former professionals Dkt. 2. Latham & Watkins LLP leads the petition's list of the 30 largest unsecured claims at $9,907,801.93, followed by Cognitive Research Corporation at $2,183,134.24 and Clark Smith Villazor LLP at $1,944,207.34 Dkt. 1. On a consolidated basis, the petition estimates 1,000 to 5,000 creditors, assets of $10 million to $50 million and liabilities of $100 million to $500 million. Its attached figures, taken from the June 30, 2026 10-Q, report assets of $28.799 million and total debts of $104.451 million.
As liquidity tightened, the lenders granted successive rounds of covenant relief. A March 2026 Ninth Amendment waived the covenant barring a going-concern qualification in BioXcel's 2025 audited financials Dkt. 2. It also cut the minimum liquidity covenant from $15 million to $12.5 million, in exchange for a $2.5 million principal prepayment and warrants issued to the lenders. A July 2026 Tenth Amendment deferred the principal and interest due June 30, 2026, reduced the minimum liquidity covenant to $7.5 million and set a July 31, 2026 deadline for BioXcel to enter a definitive strategic transaction. Amendments from June through August 2026 pushed the deferred payment to August 31, 2026, with the June 30 interest paid in kind Dkt. 2 · p. 12. A September 8 report published on Yahoo Finance, citing BioXcel's SEC filings, counted 14 amendments to the credit agreement between November 2023 and August 2026 and said quarterly amortization of 5% of principal began at the end of March 2026 finance.yahoo.com: Biotech filed for bankruptcy 11 weeks before its big FDA decision (outside source).
To bridge liquidity while that process continued, BioXcel completed a registered direct offering in March 2026 that raised approximately $6.9 million in net proceeds through placement agent Rodman & Renshaw LLC Dkt. 2. The lenders also provided $1.25 million of secured bridge financing under a further amendment to fund preparation for the filing Dkt. 274.
The existing lenders funded the case and rolled up $58.25 million of prepetition debt
BioXcel entered chapter 11 with approximately $440,000 in unrestricted cash, and without DIP proceeds its available cash would have been negative in the first four weeks, according to the Chung declaration Dkt. 25. The prepetition lenders would not consent to a priming facility from a third party, but they provided the bridge loan and committed new money. MTS contacted 11 financing parties as well as Teva. Teva declined, and no third-party DIP proposal came in.
The court entered the interim DIP order on August 31, 2026, authorizing a senior secured, superpriority priming facility of up to $77.25 million Dkt. 64. The $9.5 million initial draw was funded at closing and rolled up $29.75 million of prepetition obligations, including the $1.25 million bridge. The final order, entered September 23, 2026, permits one additional draw of up to $9.5 million, subject to the credit agreement's conditions, with a further $28.5 million roll-up when it funds Dkt. 149 · p. 2. Use of cash collateral is limited to the approved budget, tested weekly against a 15% variance on a rolling four-week basis.
- New money
- Roll-up
- New money, initial draw$9.5M
- New money, additional draw$9.5M
- Roll-up with initial draw, including $1.25M bridge$29.75M
- Roll-up with additional draw$28.5M
Total authorized$77.25M
Show the numbers
| Component | Amount |
|---|---|
| New money, initial draw | $9.5M |
| New money, additional draw | $9.5M |
| Roll-up with initial draw, including $1.25M bridge | $29.75M |
| Roll-up with additional draw | $28.5M |
| Total authorized | $77.25M |
The final order gave parties in interest with standing until November 14, 2026 to challenge the prepetition lenders' claims and liens, with an extension for any trustee appointed, or any conversion, before that date Dkt. 149. It grants the prepetition lenders replacement liens and superpriority claims for any diminution in value. It also waives the section 506(c) surcharge, the section 552(b) equities-of-the-case exception and marshaling.
Sale approval came 55 days after the petition, and closing followed within a week
| Date | Event |
|---|---|
| April 2022 | BioXcel signs the Credit Agreement and RIFA (up to $260 million); FDA approves IGALMI |
| June 29, 2023 | TRANQUILITY trial misconduct disclosed; stock falls about 64% in one day |
| August 2023 | Board approves the Clinical Reprioritization |
| December 2023 | RIFA terminated; $30 million balance converted to term loans |
| May to September 2024 | Workforce reduced 15%, then a further 28% |
| September 10, 2025 | SERENITY At-Home Phase 3 trial reports positive results |
| November 7, 2025 | MTS Health Partners retained as investment banker |
| January 2026 | Supplemental NDA submitted to FDA for at-home IGALMI use |
| March 2026 | Ninth Amendment signed; $6.9 million registered direct offering closes |
| July 1, 2026 | Strategic Process Committee formed |
| July 2026 | Tenth Amendment sets July 31 deadline for a strategic transaction |
| August 27, 2026 | BioXcel and two subsidiaries file chapter 11; CRO Samir Saleem files the first-day declaration |
| August 31, 2026 | Interim DIP order and joint administration order entered |
| September 23, 2026 | Final DIP order entered |
| September 28, 2026 | Bidding procedures order approves the Teva stalking-horse agreement |
| September 30, 2026 | Combined plan and disclosure statement filed |
| October 9, 2026 | Bid deadline passes with no other qualified bid |
| October 21, 2026 | Sale order entered; solicitation version of the plan filed |
| October 27, 2026 | Teva announces it has acquired worldwide rights to BXCL501 and IGALMI |
| November 13, 2026 | Plan supplement and proposed confirmation order filed |
| November 14, 2026 | FDA target action date for the sNDA; DIP challenge deadline |
| November 16, 2026 | Name change to BX Liquidation, Inc. authorized; Hills settlement approved |
| November 21, 2026 | Last day for FDA approval to earn the $67.5 million development payment |
| December 3, 2026 | Hearing on disclosure statement approval, confirmation and final decree motion |
Sources
- Dkt. 1BioXcel Chapter 11 PetitionFiled Aug 27, 2026Aug 27, 2026
- Dkt. 2BioXcel First-Day DeclarationFiled Aug 27, 2026Aug 27, 2026
- Dkt. 13Proposed Sale ProceduresFiled Aug 28, 2026Aug 28, 2026
- Dkt. 14Sale Process DeclarationFiled Aug 28, 2026Aug 28, 2026
- Dkt. 24Requested DIP FinancingFiled Aug 28, 2026Aug 28, 2026
- Dkt. 25Chung Declaration Supporting DIP FinancingFiled Aug 28, 2026Aug 28, 2026
- Dkt. 52Joint Administration OrderFiled Aug 31, 2026Aug 31, 2026
- Dkt. 64Interim DIP Financing OrderFiled Aug 31, 2026Aug 31, 2026
- Dkt. 149Final DIP Financing OrderFiled Sep 23, 2026Sep 23, 2026
- Dkt. 179Sale Bidding Procedures OrderFiled Sep 28, 2026Sep 28, 2026
- Dkt. 196Proposed Liquidating PlanFiled Sep 30, 2026Sep 30, 2026
- Dkt. 247Amended Liquidating PlanFiled Oct 19, 2026Oct 19, 2026
- Dkt. 258Proposed Liquidating PlanFiled Oct 20, 2026Oct 20, 2026
- Dkt. 267Sale Approval OrderFiled Oct 21, 2026Oct 21, 2026
- Dkt. 274Proposed Liquidating PlanCited at p. 30 · Filed Oct 21, 2026Oct 21, 2026
- Dkt. 315Latham Ordinary-Course DeclarationFiled Nov 5, 2026Nov 5, 2026
- Dkt. 321Retention Amounts Under SealFiled Nov 6, 2026Nov 6, 2026
- Dkt. 324BioSignal Contract Preservation ObjectionFiled Nov 12, 2026Nov 12, 2026
- Dkt. 325Motion to Close Affiliate CasesFiled Nov 12, 2026Nov 12, 2026
- Dkt. 326BioSignal Withdraws ObjectionFiled Nov 13, 2026Nov 13, 2026
- Dkt. 329MERU October Staffing ReportFiled Nov 13, 2026Nov 13, 2026
- Dkt. 330Proposed Plan SupplementFiled Nov 13, 2026Nov 13, 2026
- Dkt. 331Proposed Plan ConfirmationFiled Nov 13, 2026Nov 13, 2026
- Dkt. 332Hearing Agenda NoticeFiled Nov 16, 2026Nov 16, 2026
- Dkt. 333Settlement Approval and Stay ReliefFiled Nov 16, 2026Nov 16, 2026
- Dkt. 334Additional Appeal Record DesignationFiled Nov 16, 2026Nov 16, 2026
- Dkt. 339Corporate Name Change OrderFiled Nov 16, 2026Nov 16, 2026
- WebTeva swoops for BioXcel neuroscience assets in bankruptcy sale for up to USD 125m ahead of FDA decisionallsci.com · Outside source
- WebCooley LLP and Young Conaway Stargatt & Taylor, LLPfinanznachrichten.de · Outside source
- WebStretto, Inc. is serving as the claims and noticing agentmarkets.businessinsider.com · Outside source
- WebTeva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?insidermonkey.com · Outside source
- WebBioXcel files for bankruptcy, will sell assets to Teva for up to $125Mbiospace.com · Outside source
- WebBiopharma firm BioXcel Therapeutics files for bankruptcy in USkfgo.com · Outside source
- WebBiotech filed for bankruptcy 11 weeks before its big FDA decisionfinance.yahoo.com · Outside source